Email updates

Keep up to date with the latest news and content from Infectious Agents and Cancer and BioMed Central.

This article is part of the supplement: Proceedings of the 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access Oral presentation

A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061

John F Deeken1*, Michelle A Rudek2, Page C Moore3, David Aboulafia4, Ryan Sullivan5, John Gerecitano6, Mary Cianfrocca7, David Henry8, Lee Ratner9, Bruce Dezube5, Kimberly Mosby10, Melinda Tibbals10, Richard F Little11, S P Ivy11 and Ronald T Mitsuyasu12

Author Affiliations

1 Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA

2 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA

3 University of Arkansas for Medical Sciences, Little Rock, AR, USA

4 Virginia Mason Medical Center, Seattle, WA, USA

5 Beth Israel Deaconess Medical Center, Boston, MA, USA

6 Memorial Sloan-Kettering Cancer Center, New York, NY, USA

7 Northwestern University, Chicago, IL, USA

8 Pennsylvania Hospital, Philadelphia, PA, USA

9 Washington University, St. Louis, MO, USA

10 EMMES Corporation, Rockville, MD, USA

11 National Cancer Institute, National Institutes of Health, Rockville, MD, USA

12 University of California, Los Angeles Care Center, Los Angeles, CA, USA

For all author emails, please log on.

Infectious Agents and Cancer 2012, 7(Suppl 1):O15  doi:10.1186/1750-9378-7-S1-O15


The electronic version of this article is the complete one and can be found online at: http://www.infectagentscancer.com/content/7/S1/O15


Published:19 April 2012

© 2012 Deeken et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

In developed counties the rates of non-AIDS defining cancers (NADCs) now exceed those of AIDS-defining cancers in HIV-positive patients. Drug-drug interactions between HAART and chemotherapy may complicate the treatment of patients with NADCs. In order to determine the proper dosing of new targeted chemotherapies in patients with NADCs who are also on HAART, the AMC is performing a series of phase I/pharmacokinetic (PK) studies to determine the proper dosing of these agents in HIV+ cancer patients. We present the results of the first such study which investigated sunitinib, an oral multiple tyrosine kinase inhibitor.

Methods

Patients with HIV and cancers refractory to standard therapy were stratified into two arms: (1) non-ritonavir based HAART or (2) ritonavir-based HAART. Six patients were to be enrolled on arm 1 and receive the standard dose of sunitinib (50mg po qd). Arm 2 used a phase I, 3+3 dose escalation design (25, 37.5, and 50mg po qd). Cycles were 4 weeks on/2 weeks off. PK monitoring of sunitinb and its active metabolite (S-M) were performed throughout cycle one, and normalized based on dose level, to calculate AUC0-24, Cmax, and trough level.

Results

Between 8/09 and 4/11, 19 patients were enrolled and completed cycle 1 (10 on arm 1, 9 on arm 2). Cancer types included Kaposi’s Sarcoma (7), lung (2), anal (2), head and neck (2), NHL (1), and other solid tumors (5). Median cycles was 2 (range 1-7). Following enrollment of the first 6 patients to Arm 1, that arm was expanded to include 3 additional patients on efavirenz, a potent inducer of CYP3A4, to better characterize sunitinb-efavirenz interactions. Patients on arm 1 tolerated standard treatment of 50mg with no dose limiting toxicities (DLTs). In the ritonavir arm, three patients tolerated 25mg with no DLTs. At the 37.5mg level, one patient had a DLT (wound dehiscence) and another three of five patients experienced Grade 3 neutropenia. With 4 of 6 patients experiencing grade 3/4 toxicity, enrollment was stopped, and no further dose escalation was attempted. No patient had a CR or PR, but five patients (26%) had stable disease for >4 cycles. Grade 3/4 toxicities during cycle 1 were: neutropenia (16%), leukopenia (16%), wound complications (5%), and abdominal pain (5%). PK analysis showed significant inter-patient variability of sunitinib and S-M. There were no PK alterations of sunitinib between the arms, but there were significant alterations in the PK of S-M. Efavirenz resulted in a 220% increase, whereas ritonavir caused a 69% decrease in the AUC of S-M, respectively.

Conclusion

The recommended dose of suninitib for patients on ritonavir is 37.5mg, whereas patients on NNRTI-based therapy can be treated with the standard dose of 50mg per day.